John R. Fullarton

Aldermaston, ENG RG78AP, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 34 publications

RSV Immunoprophylaxis in Infants and Children: Old Standards, New Agents and the Complexities Therein.

RSV Immunoprophylaxis in Infants and Children: Old Standards, New Agents and the Complexities Therein.

Journal: Vaccines

Published: June 01, 2026

Optimised mesalazine therapy reduces ulcerative colitis recurrence across the mild-to-moderate disease spectrum: the IMPACT study.

Optimised mesalazine therapy reduces ulcerative colitis recurrence across the mild-to-moderate disease spectrum: the IMPACT study.

Journal: Frontiers in gastroenterology (Lausanne, Switzerland)

Published: May 06, 2026

Meta-analysis of the efficacy of palivizumab versus nirsevimab at preventing medically attended respiratory syncytial virus infections in non-hospitalized preterm infants.

Meta-analysis of the efficacy of palivizumab versus nirsevimab at preventing medically attended respiratory syncytial virus infections in non-hospitalized preterm infants.

Journal: Human vaccines & immunotherapeutics

Published: April 01, 2026

Cost-effectiveness of wastewater and environmental monitoring of respiratory syncytial virus to guide universal infant immunoprophylaxis in Canada.

Cost-effectiveness of wastewater and environmental monitoring of respiratory syncytial virus to guide universal infant immunoprophylaxis in Canada.

Journal: Journal of medical economics

Published: February 28, 2025

Clinical and economic evaluation of risk factor guided respiratory syncytial virus prophylaxis in Colombian preterm infants.

Clinical and economic evaluation of risk factor guided respiratory syncytial virus prophylaxis in Colombian preterm infants.

Journal: Cost effectiveness and resource allocation : C/E

Published: February 11, 2025

Post-Pandemic Dynamics of the Global Circulation of Human Metapneumovirus and Respiratory Syncytial Virus.

Post-Pandemic Dynamics of the Global Circulation of Human Metapneumovirus and Respiratory Syncytial Virus.

Journal: The Journal of infectious diseases

Published: December 02, 2024

Optimizing risk factors to guide COST-effective use of palivizumab in KOREAN infants.

Optimizing risk factors to guide COST-effective use of palivizumab in KOREAN infants.

Journal: Pediatrics international : official journal of the Japan Pediatric Society

Published: April 29, 2024

Opinion: The optimal use of risk factors to guide palivizumab prophylaxis against severe respiratory syncytial virus infection in moderate-to-late preterm infants.

Opinion: The optimal use of risk factors to guide palivizumab prophylaxis against severe respiratory syncytial virus infection in moderate-to-late preterm infants.

Journal: Frontiers in pediatrics

Published: November 24, 2023

A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29-35 weeks' gestational age.

A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29-35 weeks' gestational age.

Journal: PloS one

Published: May 25, 2023

Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants.

Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants.

Journal: Journal of medical economics

Published: April 17, 2023

Efficacy of oral prolonged-release mesalazine in moderately active ulcerative colitis.

Efficacy of oral prolonged-release mesalazine in moderately active ulcerative colitis.

Journal: JGH open : an open access journal of gastroenterology and hepatology

Published: January 03, 2023

Accurately Assessing the Expected Impact of Universal First Respiratory Syncytial Virus (RSV) Season Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants.

Accurately Assessing the Expected Impact of Universal First Respiratory Syncytial Virus (RSV) Season Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants.

Journal: The Journal of infectious diseases

Published: November 12, 2022

Showing 1-12 of 34

Last Updated: 09/26/2026